BTIG analyst Mark Massaro maintained a Buy rating on Exact Sciences (EXAS – Research Report) on January 5 and set a price target of $90.00. The company’s shares closed last Friday at $73.20.
According to TipRanks, Massaro is an analyst with an average return of -16.0% and a 30.80% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Cerus, and Exact Sciences.
Currently, the analyst consensus on Exact Sciences is a Strong Buy with an average price target of $92.50, representing a 26.37% upside. In a report released on January 2, Benchmark Co. also upgraded the stock to a Buy with a $91.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Exact Sciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $628.34 million and a net profit of $794 thousand. In comparison, last year the company earned a revenue of $523.07 million and had a GAAP net loss of $148.76 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exact Sciences (EXAS) Company Description:
Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer.
Read More on EXAS:
- Benchmark upgrades Exact Sciences to Buy, names best idea for 2024
- Exact Sciences upgraded to Buy from Hold at Benchmark
- Exact Sciences initiated with bullish view at Guggenheim, here’s why
- Exact Sciences initiated with bullish view at Wolfe Research, here’s why
- Exact Sciences initiated with bullish view at Wolfe Research
